LB Pharmaceuticals
LBRX
34.16
-0.10
-0.29%
LB Pharmaceuticals
US · LBRX
#3180 by market cap
Listed 2025
34.16
-0.10
-0.29%
Live - 5344 symbols - heartbeat 306s ago
· 2026-10-08 09:09
Pre-market
33.48
-1.99%
After-hours
34.16
0.00%
- Market cap
- 1.10B
- P/E (TTM)i
- -11.43
- P/Bi
- 3.32
- EPSi
- -1.00
- Div yieldi
- 0.00%
- 52W posi
- 55%
Reader sentiment
Are you bullish or bearish on LBRX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- Total institutional ownership fell 12.6 percentage points.
Institutional ownership
- Held by institutions
- 100.50% -12.64pp
- Institutions
- 146
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Hedge Fund34.31%
VC/PE Fund34.26%
Mutual Fund27.99%
Public Company2.73%
Individual/Insider0.73%
Sovereign Wealth Fund0.50%
Private Company0.48%
Insurance Company0.14%
Top holders as of 2026-06-30
Deep Track Capital, LP
10.39% · 3.35M sh
BlackRock
8.48% · 2.73M sh
RA Capital Management, L.P.
6.85% · 2.21M sh
Trails Edge Capital Partners, LP
4.72% · 1.52M sh
Commodore Capital LP
4.65% · 1.50M sh
J.P. Morgan Asset Management, Inc.
4.53% · 1.46M sh
TCG Crossover Management, LLC
4.49% · 1.45M sh
Caligan Partners, LP
4.46% · 1.44M sh
Pontifax Venture Capital
4.38% · 1.41M sh
Spruce Street Capital LP
4.27% · 1.38M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 9 sells
| Name | Role | Stake |
|---|---|---|
| Deep Track Capital, LP | -- | 10.39% |
| Heather Turner | Chief Executive Officer | 0.21% |
| Zachary Prensky | -- | 0.19% |
| Scott Garland | Independent Chairman of Board | 0.04% |
| Marc Panoff | Officer | 0.03% |
| Gad Soffer | Chief Business Officer | 0.03% |
| Anna Eramo | Chief Medical Officer | 0.01% |
| Robert Richard Ruffolo | Independent Director | 0.01% |
| David Kroin | -- | -- |
| Pontifax Venture Capital | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-29 | David Kroin | -- | Open Market Derivative Acquisiti | +286,205 | $0.00 |
| 2026-06-08 | Zachary Prensky | -- | Intent to Sell (Form 144) | -16,500 | $29.49 |
| 2026-06-02 | Robert Richard Ruffolo | Independent Director | Other Derivative Acquisition | +10,000 | $27.95 |
| 2026-06-02 | Ran Nussbaum | Independent Director | Other Derivative Acquisition | +10,000 | $27.95 |
| 2026-06-02 | William Kane | Former Independent Director | Other Derivative Acquisition | +10,000 | $27.95 |
| 2026-06-02 | Scott Garland | Independent Chairman of Board | Other Derivative Acquisition | +10,000 | $27.95 |
| 2026-06-02 | Rebecca Luse | Independent Director | Other Derivative Acquisition | +10,000 | $27.95 |
| 2026-06-02 | Rekha Hemrajani | Former Independent Director | Other Derivative Acquisition | +10,000 | $27.95 |
| 2026-06-02 | Robert Lenz | Director | Other Derivative Acquisition | +12,500 | $27.95 |
| 2026-03-05 | Robert Lenz | Director | Other Derivative Acquisition | +20,000 | $23.78 |
| 2026-02-05 | Deep Track Capital, LP | -- | Open Market Derivative Acquisiti | +472,369 | $0.00 |
| 2025-12-09 | Kaya Pai Panandiker | Chief Commercial Officer | Other Derivative Acquisition | +195,000 | $21.36 |
| 2025-09-11 | Pontifax Venture Capital | -- | Private Acquisition | +1,000,000 | $15.00 |
| 2025-09-11 | Pontifax Venture Capital | -- | Derivative Exercise and Retained | +411,681 | -- |
| 2025-09-11 | Deep Track Capital, LP | -- | Private Acquisition | +2,666,666 | $15.00 |
| 2025-09-11 | Deep Track Capital, LP | -- | Derivative Exercise and Retained | +686,138 | -- |
| 2025-09-11 | Deep Track Capital, LP | -- | Initial Statement of Beneficial | 0 | -- |
| 2025-09-09 | Robert Richard Ruffolo | Independent Director | Derivative Sale to Issuer | -13,266 | -- |
| 2025-09-09 | Robert Richard Ruffolo | Independent Director | Other Derivative Acquisition | +35,715 | $15.00 |
| 2025-09-09 | Robert Richard Ruffolo | Independent Director | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:09:08 · For reference only, not investment advice and not tailored to your situation.